A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Exclusion Criteria

• •History of hypersensitivity to any component of the investigational product.
• •Received systemic chemotherapy, targeted therapy, biological therapy or immunotherapy for anti-tumor purpose, or major surgery within 3 weeks prior to the first dose of study treatment.
• •Received anti-infection therapy within 2 weeks prior to the randomization
• •Prior treatment with MMAE/MMAF ADC drugs
• •Central nervous system metastasis.
• •Poorly controlled systemic diseases
• •Patients with poorly controlled heart diseases
• •Poorly controlled pleural and peritoneal effusion or pericardial effusion
• •≥Grade 2 toxic reaction or abnormal value of laboratory test caused by previous anti-tumor treatment
• •Patients with prior ≥Grade 3 immuno-related adverse events (irAEs)
• •Any clinically significant arteriovenous bleeding, pulmonary embolism, or deep venous thrombosis occurred within 3 months
• •Received allogeneic tissue/solid organ transplantation.
• •Inoculate live vaccine within 30 days before the first dose.
• •Patients with a positive serum pregnancy test or who are breast-feeding or who do not agree to take adequate contraceptive measures during the treatment and for 180 days after the last dose of study treatment.
• •History of other primary malignant tumor diseases.
• •Other situations that are not suitable to participate a clinical trial per investigator's judgement